Literature DB >> 26597489

Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports.

Kevin V Blake1, Agnes Saint-Raymond2, Cosimo Zaccaria2, Francois Domergue2, Benjamin Pelle2, Jim Slattery2.   

Abstract

BACKGROUND: Databases of suspected adverse drug reactions (ADRs) are a cornerstone of pharmacovigilance. With increasing numbers of reports, additional statistical approaches are needed to better use the data. AIM: The present study was aimed at elucidating the European Medicines Agency's (EMA) use of a novel 'paediatric' query to analyse the data in its ADR database 'EudraVigilance'.
METHODS: The proportional reporting ratio (PRR) is a measure of disproportionality for which the underlying principle is that a drug-event pair of interest is reported more often than expected relative to an independence model. The EMA's paediatric query, based on PRRs, was applied to the data in EudraVigilance to investigate the extent to which the known association between enalapril and renal toxicity was reflected in reported ADRs comparing children with adults and with adjustment for the effect of multiplicity.
RESULTS: The comparison of PRRs for children (14.91, 95% confidence interval [CI] 13.05-17.04) versus adults (2.66, 95% CI 2.52-2.82) confirmed a higher risk of renal ADRs with enalapril when used in children compared with all other medicines and compared with adults.
CONCLUSIONS: The EMA's paediatric query can be used to highlight an imbalance for a drug-event pair among ADRs for a medicine when used in children and as compared with adults. Applying the query in practice can help the EMA to decide on whether stand-alone paediatric medicine development is warranted, and which, if any, further studies are necessary. Ongoing evaluation of the query is contributing to the development of new methods and guidance.

Entities:  

Mesh:

Year:  2016        PMID: 26597489     DOI: 10.1007/s40272-015-0154-0

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  9 in total

1.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

Review 2.  High blood pressure in children and adolescents.

Authors:  Margaret Riley; Brian Bluhm
Journal:  Am Fam Physician       Date:  2012-04-01       Impact factor: 3.292

3.  Angiotensin Converting Enzyme Inhibitor (ACEI)-Induced Acute Renal Failure in Premature Newborns with Congenital Heart Disease.

Authors:  Grace J Lee; Risa Cohen; Anthony C Chang; John P Cleary
Journal:  J Pediatr Pharmacol Ther       Date:  2010-10

4.  Use of enalapril in neonatal hypertension.

Authors:  J L Schilder; J N Van den Anker
Journal:  Acta Paediatr       Date:  1995-12       Impact factor: 2.299

5.  Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension.

Authors:  Empar Lurbe; Renata Cifkova; J Kennedy Cruickshank; Michael J Dillon; Isabel Ferreira; Cecilia Invitti; Tatiana Kuznetsova; Stephane Laurent; Giuseppe Mancia; Francisco Morales-Olivas; Wolfgang Rascher; Josep Redon; Franz Schaefer; Tomas Seeman; George Stergiou; Elke Wühl; Alberto Zanchetti
Journal:  J Hypertens       Date:  2009-09       Impact factor: 4.844

6.  Renin-angiotensin system in neonatal rats: induction of a renal abnormality in response to ACE inhibition or angiotensin II antagonism.

Authors:  P Friberg; B Sundelin; S O Bohman; A Bobik; H Nilsson; A Wickman; H Gustafsson; J Petersen; M A Adams
Journal:  Kidney Int       Date:  1994-02       Impact factor: 10.612

7.  Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease.

Authors:  Katherine A Lindle; Kim Dinh; Brady S Moffett; W Buck Kyle; Natalie M Montgomery; Susan D Denfield; Jarrod D Knudson
Journal:  Pediatr Cardiol       Date:  2014-03       Impact factor: 1.655

8.  Enalapril-induced acute renal failure in a newborn infant.

Authors:  Sourabh Dutta; Anil Narang
Journal:  Pediatr Nephrol       Date:  2003-04-16       Impact factor: 3.714

9.  Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.

Authors:  Kevin V Blake; Cosimo Zaccaria; Francois Domergue; Edith La Mache; Agnes Saint-Raymond; Ana Hidalgo-Simon
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.930

  9 in total
  7 in total

1.  A Comparison of Pediatric and Adult Safety Studies for Antipsychotic and Antidepressant Drugs Submitted to the United States Food and Drug Administration.

Authors:  Xiaomei I Liu; Paul Schuette; Gilbert J Burckart; Dionna J Green; Julie La; Janelle M Burnham; Natella Rakhmanina; Adelaide Robb; Shiew Mei Huang; John N van den Anker
Journal:  J Pediatr       Date:  2019-01-21       Impact factor: 4.406

Review 2.  Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.

Authors:  Paolo A Tomasi; Gunter F Egger; Chrissi Pallidis; Agnes Saint-Raymond
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

3.  Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies.

Authors:  Anthony J Garcia-Prats; Nicole Salazar-Austin; James H Conway; Kendra Radtke; Sylvia M LaCourse; Elizabeth Maleche-Obimbo; Anneke C Hesseling; Rada M Savic; Sharon Nachman
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

4.  Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.

Authors:  Lovisa Sandberg; Henric Taavola; Yasunori Aoki; Rebecca Chandler; G Niklas Norén
Journal:  Drug Saf       Date:  2020-10       Impact factor: 5.606

5.  Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre.

Authors:  Kristina Star; Lovisa Sandberg; Tomas Bergvall; Imti Choonara; Pia Caduff-Janosa; I Ralph Edwards
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-15       Impact factor: 2.890

6.  Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports.

Authors:  Esmé J Baan; Veronique A de Smet; Christina E Hoeve; Alexandra C Pacurariu; Miriam C J M Sturkenboom; Johan C de Jongste; Hettie M Janssens; Katia M C Verhamme
Journal:  Drug Saf       Date:  2020-01       Impact factor: 5.606

Review 7.  No population left behind: Improving paediatric drug safety using informatics and systems biology.

Authors:  Nicholas P Giangreco; Jonathan E Elias; Nicholas P Tatonetti
Journal:  Br J Clin Pharmacol       Date:  2021-01-19       Impact factor: 3.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.